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Spondylo-meta-epiphyseal dysplasia (SMED) with short limbs and abnormal calcifications (SMED-SL) is a
rare, autosomal recessive human growth disorder, characterized by disproportionate short stature, short
limbs, short broad fingers, abnormal metaphyses and epiphyses, platyspondyly and premature calcifica-
tions. Recently, three missense mutations and one splice-site mutation in the DDR2 gene were identified
as causative genetic defects for SMED-SL, but the underlying cellular and biochemical mechanisms were
not explored. Here we report a novel DDR2 missense mutation, c.337G>A (p.E113K), that causes SMED-SL
in two siblings in the United Arab Emirates. Another DDR2 missense mutation, c.2254C>T (p.R752C), match-
ing one of the previously reported SMED-SL mutations, was found in a second affected family. DDR2 is
a plasma membrane receptor tyrosine kinase that functions as a collagen receptor. We expressed DDR2 con-
structs with the identified point mutations in human cell lines and evaluated their localization and functional
properties. We found that all SMED-SL missense mutants were defective in collagen-induced receptor acti-
vation and that the three previously reported mutants (p.T713I, p.I726R and p.R752C) were retained in the
endoplasmic reticulum. The novel mutant (p.E113K), in contrast, trafficked normally, like wild-type DDR2,
but failed to bind collagen. This finding is in agreement with our recent structural data identifying Glu113
as an important amino acid in the DDR2 ligand-binding site. Our data thus demonstrate that SMED-SL can
result from at least two different loss-of-function mechanisms: namely defects in DDR2 targeting to the
plasma membrane or the loss of its ligand-binding activity.
INTRODUCTION
The discoidin domain receptors (DDRs), DDR1 and DDR2,
comprise a family of receptor tyrosine kinases (RTKs) that
function as collagen receptors (1,2). The DDRs are the only
RTKs that are activated by a component of the extracellular
matrix. Several collagen types, both fibrillar and non-fibrillar
types, activate the DDRs, with the two receptors displaying
different specificities for certain collagen types (1–4). Structu-
rally, the DDRs are characterized in their extracellular regions
by the presence of a collagen-binding discoidin homology
domain and a domain unique to the DDRs (stalk region)
(Fig. 1). A transmembrane region is followed by a large cyto-
plasmic juxtamembrane domain, and, finally a C-terminal
tyrosine kinase domain. Both DDRs form ligand-independent
dimers on the cell surface (5). We have recently defined the
mode of collagen recognition by the discoidin domain of
DDR2 using X-ray crystallography (6).
The DDRs control fundamental cellular processes including
cell proliferation, adhesion and migration (7,8). In addition,
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the DDRs regulate extracellular matrix remodeling by control-
ling matrix metalloproteinase expression and activity. Both
receptors are associated with human diseases, including fibrotic
disorders of the lung (DDR1), liver (DDR2) and kidney
(DDR1); atherosclerosis (DDR1); osteoarthritis (DDR2); rheu-
matoid arthritis (DDR2); and several types of malignancies (7).
DDR2, like DDR1, is widely expressed in different tissues
during development and in postnatal tissues (7). While DDR1
is mostly confined to epithelial cells and leukocytes, DDR2 is
found on cells of mesenchymal origin. Mice lacking DDR2
exhibit dwarfism (9,10), indicating that DDR2 plays an impor-
tant role in bone growth. Labrador et al. (9) showed that tar-
geted deletion of Ddr2 in mice led to shortened long bones
due to reduced chondrocyte proliferation. In another study,
Kano et al. (10) characterized a spontaneously occurring,
autosomal-recessive mutation in their mouse colony that led
to a 150 kb deletion encompassing the first 17 exons of the
Ddr2 gene. These latter mice, termed slie mutant mice, were
infertile in addition to being dwarfed (10).
Recently, DDR2 function has been implicated in human
skeletal growth. Three DDR2 gene missense mutations and
one splice site mutation were each shown to cause spondylo-
meta-epiphyseal dysplasia (SMED) with short limbs and abnor-
mal calcifications [SMED-SL (MIM 271665)] (11). SMED-SL
is a rare, autosomal recessive, human growth disorder. Patients
exhibit normal intelligence, disproportionate short stature, pla-
tyspondyly, abnormal epiphyses and metaphyses, narrow
chest, shortening of the lower and upper limbs, short broad
fingers and premature calcifications (12,13).
DDR2 is a member of the subfamily of RTKs that also
include ROR2. Mutations in the ROR2 gene have been shown
to be the underlying cause of the recessive form of Robinow
Syndrome, a skeletal dysplasia characterized by short stature,
limb shortening, genital hypoplasia and craniofacial abnormal-
ities (14). We have recently shown that all the missense patho-
genic mutations in ROR2 are retained in the endoplasmic
reticulum (ER) and are substrates for the ER quality control
system, demonstrating that ER retention is the underlying cellu-
lar mechanism of this condition (15,16) (Ali et al., unpublished
data). Given the phylogenetic relatedness of DDR2 to ROR2,
we reasoned that most SMED-SL causing missense mutations
in DDR2 are likely to result in the retention of DDR2 protein
in the ER. In addition, patients with SMED-SL phenotype
have been reported in the United Arab Emirates (UAE), but
the molecular defects responsible for their symptoms have not
been established (17) (Al-Gazali et al., unpublished data). In
this article, we report the evaluation of two families from the
UAE with SMED-SL and the identification of two mutations
including a novel missense mutation in DDR2. In addition,
we report the elucidation of the cellular and biochemical mech-
anisms of all the missense mutations so far found in patients
with this condition. While the previously established
SMED-SL DDR2 mutations indeed caused ER retention of
mutated DDR2, we demonstrate that the novel SMED-SL
mutation (p.E113K) resulted in a ligand-binding defect. These
latter data fit well with our recent structural data on the ligand-
binding site of DDR2 (6). Furthermore, our data demonstrate
further the widespread involvement of the ER quality control
systems in the cellular mechanisms of numerous secretroy
pathway targeted proteins (15,18–20).
RESULTS
Clinical characteristics of patients with SMED-SL
from United Arab Emirates
Two consanguineous families with SMED-SL from the UAE
have been evaluated (see Supplementary Material, Fig. S1
for the pedigrees). The first is a Pakistani family with two
affected children. The clinical details of the affected children
are described in detail below. The second family is of Egyp-
tian background with two affected children and was described
in detail before (17). The family was found to have the same
mutation, c.2254C.T (p.R752C), as found in the Palestinian
families described by Bargal et al. (11). The severity of the
clinical features in this family, particularly the degree of chon-
dral calcifications, was also similar to the clinical features of
the families described by Bargal et al. (11). Both children in
this family died, one at the age of 13 years due to respiratory
complications and the other one died suddenly at 8 years of
age due to cord compression.
Family 1, Case 1. This male child was the product of normal
pregnancy. Delivery at term was by lower section Cesarean
section. Prenatal ultrasound showed short limbs and short
stubby hands. His birth weight was 2700 gm (5%) and
length was 47 cm (10%). At birth, he was noted to have in
addition to the short limbs and short hands, bowing of the
lower limbs. The diagnosis of achondroplasia was suggested.
During the first year of life and the early childhood years,
he had repeated chest infections which were not severe
enough to require hospital admissions. These attacks got
better with time and stopped when he was 6 years old. His
early developmental milestones were normal. He was operated
on both legs to correct the bowing. He was evaluated by us at
the age of 9.5 years. His weight was 27.5 kg (10%) and height
was 99 cm (≪ , 3%, 26 SD). He had dysmorphic features
Figure 1. Schematic domain structure of homodimeric DDR2. The extracellu-
lar domain consists of a collagen-binding discoidin domain, followed by a
so-called stalk region. The intracellular domain contains a large cytosolic jux-
tamembrane domain in addition to the C-terminal tyrosine kinase domain. The
position of disease-causing missense mutations is shown at the left.
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and shortening of all limbs with very short puffy hands
(Table 1). He was attending normal school at the appropriate
grade and was top of the class. Neurological examination
was normal. Skeletal survey revealed changes typical of
SMED-SL including short and broad long bones with irregular
flared metaphyses of the proximal and distal ends and genu
varum (Table 1). There was a small thoracic diameter with
short and broad ribs with very few calcifications at the costo-
chondral margin (Fig. 2A).
Family 1, Case 2. Brother of case 1, the product of normal
pregnancy and term delivery by LCS. His weight was 2.9 kg
(10%) and length was 49 cm (25%). Short limbs and short
hands were diagnosed prenatally. He was found to have
bowing of limbs in addition to the shortening. He had,
similar to his brother, repeated respiratory infections not
requiring hospital admissions. He was evaluated by us at 8
years of age. His weight was 17.6 kg (,5%) and height was
94 cm (,3%, 26 SD). He had similar dysmorphic features
as his brother but his chest appeared much narrower than his
brother’s. He was attending normal school at the appropriate
grade and was top of the class. Neurological examination
was normal. Skeletal survey revealed similar changes to his
brother (Fig. 2B and Table 1).
Molecular analysis reveals that SMED-SL in families from
the UAE is caused by two missense mutations in DDR2
The genomic DNA from SMED-SL affected individuals and
their parents (Supplementary Material, Fig. S1) was isolated
and all the exons and flanking regions of the DDR2 gene
were amplified by PCR as described in the Materials and
Methods. Direct DNA sequencing revealed two homozygous
missense mutations: c.337G.A (p.E113K) for family 1 and
c.2254C.T (p.R752C) for family 2 (Supplementary Material,
Fig. S2). The parents in each case were heterozygous for the
mutation found in their affected offspring. The nucleotide
change c.337G.A has not been found in 100 ethnically
matched controls. In addition, the p.E113K mutation is
novel and is located in the ligand-binding domain of the
DDR2 protein (Fig. 1). The amino acid change is physio-
chemically significant (a change of the negatively charged
glutamic acid to the positively charged lysine) and affects an
important residue within the discoidin domain, the DDR2
ligand-binding domain (6). Furthermore, this residue is con-
served in the DDR2 protein from different species including
zebrafish, mouse and human (Supplementary Material,
Fig. S3). These pieces of data together with the functional
assays described below confirm the pathogenicity of this
amino acid substitution. On the other hand, the mutation
(p.R752C) found in the family of Egyptian origin is a recurring
mutation and has been recently found as a founder mutation in
five Palestinian families from Jerusalem (11). This mutation is
located in the DDR2 intracellular domain, as shown in Figure 1.
SMED-SL missense mutations p.T713I, p.I726R and
p.R752C lead to loss of plasma membrane expression of
DDR2 and accumulation in the endoplasmic reticulum,
while the p.E113K mutant exhibits similar subcellular
localization as the wild-type protein
We hypothesized that most of the missense mutations in
DDR2 (Fig. 1) will result in the retention of the mutated
protein in the ER. This assumption was based on the related-
ness of DDR2 to ROR2 and our findings that all the patho-
genic missense mutations in ROR2 have been shown to be
retained in the ER (15,16). Therefore, we generated all the
missense mutations found in SMED-SL patients including
Table 1. Clinical features of the two new cases compared to the literature (11–13,17,31–34)
Features Case 1 Case 2 Literature (24 cases)
Clinical
Short limbs + + 24/24
Short broad hands + + 24/24
Short puffy fingers + + 10/24
Bowing of legs + + 7/24
Narrow chest 2 + 18/24
Pectus excavatum 2 +carinatum 8/24
Respiratory problems Mild Mild 12/24
Hypertelorism + + 20/24
Short flat nose + + 21/24
Wide nostril 2 2 18/24
Long philtrum 2 2 18/24
Short neck + + 8/24
Neck hyperextension 2 2 4/24
Peculiar voice + 2 5/23
Delayed motor development 2 2 17/24
Delayed mental development 2 2 4/24
Radiological
Short and broad long bones + + 24/24
Short and broad round bones + + 24/24
Abnormal metaphyses & epiphyses + + 24/24
Rib abnormalities + + 24/24
Chondral calcification + (minimal) + (minimal) 10/24
Platyspondyly + + 24/24
C1–C2 instability 2 2 13/24
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those reported by Bargal et al. (11) in a mammalian expression
system using site-directed mutagenesis and expressed the pro-
teins in HeLa cells as described in the Materials and Methods.
Confocal microscopy imaging revealed that the C-terminally
HA-tagged wild-type DDR2 protein was primarily localized
to the cell surface and colocalized with the plasma membrane
marker GFP-h-Ras (Fig. 3A–C). We also observed some
intracellular staining of the wild-type protein which presum-
ably represents the newly synthesized protein that is in
transit to the cell surface. Similarly, the p.E113K mutant
was located to the periphery of the cell and colocalized
with GFP-h-Ras (Fig. 3D–F). In contrast, confocal imaging
of p.T713I, p.I726R and p.R752C mutants revealed an
intracellular and reticular localization of the proteins, which is
clearly different from that of the wild-type protein, with no
colocalization with the plasma membrane marker (Fig. 3G–
O). This intracellular staining is reminiscent of ER staining
and we therefore co-stained cells expressing the wild-type
and mutant proteins with a well established ER marker (cal-
nexin). As shown in Figure 4A–F, the wild-type protein and
p.E113K mutant showed distinct and different localizations
from that of calnexin, confirming plasma membrane locations.
On the other hand, the three intracellular missense mutants
(p.T713I, p.I726R and p.R752C) showed a high degree of colo-
calization with the ER marker (Fig. 4G–O) indicating ER local-
ization. Further biochemical studies (the following sections)
confirmed the ER localization of the three proteins.
Lack of collagen-induced transmembrane signaling is due to
trafficking defects of the DDR2 mutants p.T713I, p.I726R
and p.R752C. The first step in collagen-induced DDR2 trans-
membrane signaling is activation of DDR2, which manifests
itself in autophosphorylation of cytoplasmic tyrosine residues
(1,2). To analyze whether SMED-SL disease mutants could be
activated by binding to collagen, we transiently expressed the
mutants and wild-type DDR2 in HEK293 cells. HEK293 cells
were chosen for these experiments, as DDR autophosphoryla-
tion in these cells can be easily monitored by western blotting
of cell lysates (1,21). In transfected HEK293 cells, wild-type
DDR2 is usually observed as a mixture of three (sometimes
four) molecular weight forms between 125 and 130 kDa
(5,21,22), with the upper forms representing complex glycosy-
lated mature forms. Unlike wild-type DDR2, however, for
which the expected molecular weight forms were detected
(Fig. 5A), the SMED-SL mutants p.T713I, p.I726R and
p.R752C were detected predominantly as the lowest molecular
weight species (Fig. 5A), with mutants p.T713I and p.I726R
displaying a small amount of the middle forms. None of
these mutants displayed the highest molecular weight form
of DDR2. In addition, Endo H treatment of cell lysates expres-
sing wild-type or mutant DDR2 showed that the predominant
forms of T713I-DDR2, I726R-DDR2 and R752C-DDR2 were
sensitive to Endo H digestion, as was the lowest molecular
weight form of wild-type DDR2 (Fig. 5A), suggesting that
these molecular weight species represent immature biosyn-
thetic precursors of DDR2. This is in agreement with the
protein localization data in HeLa cells, presented in
Figures 3 and 4. The predominant forms of wild-type
DDR2, however, were the upper molecular weight species,
which were largely absent in the mutant receptors. These
forms were Endo H resistant and thus represent the complex
glycosylated mature forms of DDR2.
As expected, a strong collagen-induced phosphorylation
signal was observed for the upper forms of wild-type DDR2
(Fig. 5B, upper blot lanes 1 and 2). In keeping with the lack
of plasma membrane localization of T713I-DDR2,
I726R-DDR2 and R752C-DDR2, no collagen I-induced phos-
phorylation could be detected for any of these mutant recep-
tors (Fig. 5B, upper blot lanes 3–7).
Loss of E113K-DDR2 transmembrane signaling despite
normal cellular trafficking. In contrast to mutants
T713I-DDR2, I726R-DDR2 and R752C-DDR2, which displayed
Figure 2. Chest and hand radiographs of cases 1 and 2. (A) Chest radiograph
of case 1 at 9.5 years. Narrow thorax with short broad ribs, more at the lateral
and anterior aspects (thin arrows) than at the costo-vertebral joints. Note very
few calcifications at the costal cartilage on the right side (arrow heads). Note
also irregularities at the humeral meta/epiphyses with calcifications (thick
arrows). (B) Radiograph of the left hand (dorso-volar projection) of case 2
at 8 years of age showing short and broad tubular bones with typical diaphy-
seal constriction (medium arrow). The metacarpal bones are narrower at the
proximal end giving the appearance of drumsticks (thick arrow). There is
some bone-within-bone appearance of the phalanges (medium arrow). The
distal phalanges are triangular in shape. The epiphyses of the phalanges
appear irregular and cone-shaped (arrow head). Small and irregular precocious
carpal bones. The distal metaphyses of the radius and ulna is broad and irre-
gular with irregular trabecular structure. The distal ulnar epiphysis is triangular
in shape (thin arrow).
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predominant ER localization, E113K-DDR2 was found on the
plasma membrane in HeLa cells (Figs 3 and 4). Transient
expression of E113K-DDR2 in HEK293 cells resulted in the
appearance of the same molecular weight forms as observed for
wild-type DDR2, with only the lowest molecular weight form
showing sensitivity to Endo H treatment (Fig. 6A). The upper
Figure 3. Comparison of subcellular localization of DDR2 wild-type and SMED-SL patient mutant variants. HeLa cells were transiently co-transfected with plasmids
encoding the indicated HA-tagged DDR2 protein and EGFP-tagged H-Ras, fixed and stained with anti-HA antibodies as described in Materials and Methods. (A), (D),
(G), (J) and (M) show the distribution of over-expressed HA-tagged DDR2 proteins. (B), (E), (H), (K) and (N) show the distribution of over-expressed EGFP-tagged
H-Ras, which is predominantly localized to the plasma membrane, while (C), (F), (I), (L) and (O) show the extent of co-localization of DDR2 proteins with EGFP-H-Ras.
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Figure 4. Comparison of the intracellular localization of DDR2 wild-type and SMED-SL patient mutant variants with the ER marker. HeLa cells were transiently
transfected with plasmids encoding the indicated HA-tagged DDR2 protein, fixed and stained with antibodies against the HA-tag (monoclonal) and calnexin
(polyclonal) as described in Materials and Methods. (A), (D), (G), (J) and (M) show the distribution of over-expressed HA-tagged DDR2 proteins. (B), (E),
(H), (K) and (N) show the distribution of calnexin, which is predominantly localized to the ER, while (C), (F), (I), (L) and (O) show the extent of co-localization
of DDR2 proteins with calnexin.
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species of E113K-DDR2 are thus complex glycosylated and
likely represent mature forms of the receptor. Unlike wild-type
DDR2, however, E113K-DDR2 could not be activated by col-
lagen I. Even at high concentrations of collagen I (50 mg/ml),
no collagen I-induced phosphorylation signal was detected
(Fig. 6B), indicating that plasma-membrane localized
E113K-DDR2 is defective in transmembrane signaling.
Loss of ligand binding of E113K-DDR2. We recently ident-
ified glutamate 113 as one of the major collagen-binding resi-
dues in DDR2 (6). Glu113 forms a salt bridge with Arg105 in
the DDR2 discoidin domain. Substitution of the glutamate
by lysine would disrupt the salt bridge and is expected to
negatively impact on ligand binding by E113K-DDR2. To
analyze the effect of p.E113K substitution on DDR2 collagen
binding, we created a soluble ectodomain construct with the
p.E113K mutation and expressed it in HEK293-EBNA cells.
This construct was secreted at similar levels to the correspond-
ing wild-type protein, indicating that the mutation did not
result in gross abnormalities of protein folding. The mutant
protein failed to bind to collagens types I and II in an estab-
lished solid-phase binding assay, displaying similar low-level
binding to a DDR2 variant harboring the p.W52A mutation
(Fig. 7B and C). We and others recently showed that Trp52,
like Glu113, plays a critical role in collagen recognition by
DDR2, and that substitution of Trp52 by Ala abolishes col-
lagen I and collagen II binding (6,23). We conclude that sub-
stitution of Glu113 by Lys leads to loss of ligand binding,
which in turn is responsible for lack of collagen-induced
signaling of full-length E113K-DDR2.
Figure 5. Defective cellular trafficking causes loss of collagen-induced signal-
ing for the SMED-SL patient mutant variants T713I-DDR2, I726R-DDR2 and
R752C-DDR2. HA-tagged full-length DDR2 wild-type or mutant variants
were transiently expressed in HEK293 cells. (A) Cell lysates were treated
with Endoglycosidase H for 3 h at 378C (H) or left untreated for 3 h at
378C (2) and analyzed by SDS–PAGE and western blotting. The blot was
probed with polyclonal anti-DDR2 antibodies. (B) Cells were stimulated
with 10 mg/ml of rat tail collagen I (+) or 1 mM acetic acid (2) for 90 min
at 378C. Cell lysates were analysed by SDS–PAGE and western blotting.
The blots were probed with anti-phosphotyrosine (anti-PY) monoclonal anti-
body 4G10 (upper blot) or polyclonal anti-DDR2 antibodies (lower blot).
The positions of molecular markers (in kDa) are indicated. The experiments
were carried out three times with very similar results.
Figure 6. Loss of collagen-induced signaling despite normal cellular traffick-
ing of E113K-DDR2. Untagged full-length DDR2 wild-type or E113K-DDR2
were transiently expressed in HEK293 cells. (A) Cell lysates were treated with
Endoglycosidase H for 3 h at 378C (H) or left untreated for 3 h at 378C (2)
and analyzed by SDS–PAGE and western blotting. The blot was probed
with polyclonal anti-DDR2 antibodies. (B) Cells were stimulated for 90 min
at 378C with rat tail collagen I at the indicated concentrations (in mg/ml).
Cell lysates were analyzed by SDS–PAGE and western blotting. The blots
were probed with anti-phosphotyrosine (anti-PY) monoclonal antibody 4G10
(upper blot) or polyclonal anti-DDR2 antibodies (lower blot). The positions
of molecular markers (in kDa) are indicated. The experiments were carried
out three times with very similar results.
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DISCUSSION
Here we report the clinical features of two siblings diagnosed
with SMED-SL and a novel DDR2 missense mutation ident-
ified in these patients. This mutation (p.E113K) is located in
the extracellular discoidin domain and affects a surface-
exposed residue that was previously identified as an important
amino acid in the collagen-binding site of DDR2 (6,23).
Additionally, we identified another mutation (p.R752C) in an
Egyptian family with SMED-SL. This DDR2 mutation, loca-
lized in exon 17 of the DDR2 gene, which encodes part of
the intracellular tyrosine kinase domain, is a recurring
mutation previously found in five Arab families from Jerusa-
lem affected with SMED-SL (11).
Here we demonstrate the effects of all known SMED-SL
causing missense mutations on DDR2. Our cellular and bio-
chemical analysis of these four DDR2 mutations showed that
these fall into two classes: all previously identified missense
mutations cause a trafficking defect with the affected proteins
mis-localizing to the ER, while the novel p.E113K-DDR2
mutation is localized in the cell similar to wild-type DDR2
but is defective in transmembrane signaling due to a ligand-
binding defect. A previous report identified mutations in the
DDR2 gene as causative genetic defects for SMED-SL (11),
but did not illuminate the mechanism of disease. Bargal et al.
(11) speculated on the possible biochemical consequences of
the disease mutations p.T713I, p.I726R and p.R752C.
Because the affected amino acids are located in the active site
of the DDR2 kinase, it was proposed that the substitutions
may influence the stability of the activation loop, ATP
binding affinity or substrate specificity, respectively (11). The
possibility that protein folding may be affected was not con-
sidered. DDR2 is a member of the RTK family of plasma mem-
brane receptors and is phylogenetically related to ROR2 (24).
Missense mutations in the ROR2 gene were recently shown to
cause retention of the mutated proteins in the ER as a result
of the protein folding quality control within this organelle
named ER-Associated Protein Degradation (ERAD) (15,16).
ERAD ensures that only properly folded proteins and fully
assembled complexes are allowed to exit the ER to their final
destinations. Proteins that fail to attain the required functional
native conformations due to mutations or failure to acquire
the needed posttranslational modifications, such as proteolytic
cleavage of signal peptides, glycosylation and GPI-anchoring,
are retained in the ER for a short period of time but then get
targeted for re-translocation to the cytoplasm and degradation
by the ubiquitin/proteasome systems (25–29).
In this report, we show that three out of four missense
mutations (p.T713I, p.I726R and p.R752C) found in
SMED-SL patients result in the retention of the affected pro-
teins in the ER. ER retention of the three mutants is strongly
supported by the confocal images presented in Figures 3 and
4 and the biochemical findings on the sensitivity to Endo H
treatment presented in Figure 5. We noticed lower levels of
expression of the ER-retained mutant proteins in HEK293
cells, compared with wild-type DDR2, as can be seen in
Figure 5B. These low steady-state levels of the mutant pro-
teins may be due to ERAD degradation. Additionally, our find-
ings add another genetic condition to the 60 or so known to be
caused by ERAD (15,18,19,30).
Unlike the ER-retained mutant DDR2 receptors,
E113K-DDR2 was found at the cell surface, similar to wild-
type DDR2 (Fig. 3A–F), indicating a different disease-causing
mechanism. Glu113 is located in the DDR2 extracellular dis-
coidin domain. The DDR2 discoidin domain adopts a b-barrel
structure consisting of eight b-strands (23). At the top of the
barrel, five protruding loops create a trench that forms the
collagen-binding site (6,23). Glu113, which forms a salt
bridge with Arg105, is one of several key residues that
contact collagen (6). Figure 8, which shows a cartoon
drawing of the DDR2 discoidin domain bound to a collagen
peptide, illustrates how Glu113 is involved in the DDR2-
collagen interaction. Data presented in Figure 7 demonstrate
that E113K-DDR2 had lost most of the collagen-binding
activity. This result agrees well with the previous observation
that mutation of E113Q reduced collagen-binding to 10% of
wild-type DDR2 (23). Thus, Glu113 is one of the main DDR2
residues contributing to collagen-binding. It is also noted that
Glu113 and Arg105 are conserved in DDR1, further under-
scoring the importance of the Glu113-Arg105 salt bridge in
the DDR-collagen interaction. This is the first report on the
clinical relevance of substitutions at this site.
We noted some variations in the phenotype between the two
families we are reporting here. For example, the clinical phe-
notype and the degree of chondral calcification of the second
family (mutation p.R752C) were very severe (17). Both chil-
dren had extensive calcifications which appeared by 1 years
Figure 7. Loss of collagen-binding function of E113K-DDR2. (A) SDS–poly-
acrylamide gel electrophoresis of purified WT-DDR2-Fc, E113K-DDR2-Fc
and W52A-DDR2-Fc. A Coomassie-blue-stained gel (7.5% gel) is shown.
The positions of molecular weight markers (in kDa) are indicated. (B and
C) Solid phase binding assays with recombinant wild-type DDR2-Fc,
E113K-DDR2-Fc or W52A-DDR2-Fc. Recombinant DDR2 ectodomain pro-
teins were added for 3 h at room temperature to 96-well plates coated with col-
lagen I (B) or collagen II (C) at 10 mg/ml. Shown are the means+SEM of
three independent experiments, each performed in duplicates.
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of age and were very progressive and widespread involving
almost all cartilages. In addition, both children had repeated
respiratory infections requiring hospital admissions and
leading to death in the older child. The younger sib had in
addition symptoms of cord compression, which led to his
sudden death. The phenotype in the affected children from
the first family (mutation p.E113K), on the other hand, was
less severe with very few mild respiratory infections not
requiring hospital admissions. In addition, the chondral calci-
fication was limited and much less severe than in the p.R752C
family. This variability might be due to retention of some
residual activity in the p.E113K mutant compared with the
p.R752C mutant. Alternatively, cells expressing the
ER-retained mutated protein (p. R752C) may experience ER
stress, which would not be experienced by cells expressing
the correctly targeted p.E113K protein. However, the clinical
significance of these presumed differences in ER stress
responses are unknown at this stage.
How does DDR2 control bone growth? Very little is known
about the role of DDR2 in bone growth. DDR2 is expressed on
chondrocytes and its elimination in the mouse leads to suppres-
sion of chondrocyte cell proliferation (9). It is assumed that the
interaction of DDR2 with collagen II in the proliferative zone of
the growth plate is responsible for controlling chondrocyte pro-
liferation. DDR2 is also a receptor for another collagen type
with relevance to bone growth, collagen X (4). While collagen
II is found in all types of cartilage, collagen X expression is
restricted to the hypertrophic zone of the growth plate. We
show here that E113K-DDR2 is unable to interact with collagen
II (Fig. 7C). Further studies are required to establish whether the
mutant protein is also defective in binding to collagen X.
In mice with targeted DDR2 deletion, the growth plates were
observed to be shortened (9). In the only available histological
study of a chostrochondral junction from a SMED-SL patient,
extremely abnormal cartilage was found (12). The growth
plate was found to lack proliferating chondrocyte columns.
Chondrocytes were small and sparse in the resting zone, often
surrounded by a ‘ring-like’ amorphous matrix, which in turn
could be surrounded by a more densely packed structure of
fibrillar collagen. Clustering of chondrocytes within lacunae
was also observed. Taken together with our data, it can be
speculated that in SMED-SL patients, lack of DDR2 interaction
with collagen II results in impaired DDR2 signaling, leading to
severe suppression of chondrocyte proliferation, which may be
responsible for poor linear bone growth. Further morphological
studies on patient samples with known DDR2 mutations would
be required to confirm this hypothesis.
In summary, we report a novel mutation in the DDR2 gene
in patients affected with SMED-SL and elucidate the cellular
and biochemical mechanisms underlying all reported
SMED-SL disease mutations. Two different mechanisms,
failure to reach the plasma membrane and impaired ligand
binding, were found to result in the growth disorder. This
study supports the notion that DDR2 signaling is important
in human development and that the interaction of DDR2
with collagen is essential for proper skeletal growth.
MATERIALS AND METHODS
Patients
The research was approved by Al-Ain Medical District Human
Research Ethics Committee and informed consent was obtained
from the parents. Patients were evaluated by a clinical geneticist
and their radiography imaging were also evaluated.
Chemicals and reagents
Bovine serum albumin was obtained from Fisher Scientific
(Loughborough, UK). Collagen I (acid-soluble from rat tail;
C-7661) was purchased from Sigma (Poole, UK). Bovine col-
lagen II, ELISA grade, was from Chondrex Inc. (Redmond,
WA, USA). Endoglycosidase H (Endo Hf) was purchased
from New England Biolabs (Hertfordshire, UK). The antibodies
and their sources were as follows: antibodies for immunofluor-
escence: mouse anti-HA-Tag monoclonal antibody (dilution
1:200; Cell Signaling Technology), rabbit anti-calnexin poly-
clonal antibody (dilution 1:500; StressGen Biotechnologies),
Alexa Fluor 568-goat anti-mouse IgG (dilution 1:200; Molecu-
lar Probes), Alexa Fluor 488-goat anti-rabbit IgG (dilution
1:200; Molecular Probes). Antibodies for western blotting:
goat-anti-DDR2 (AF2538) was from R&D Systems (Abingdon,
UK); mouse anti-phosphotyrosine, clone 4G10, from Upstate
Biotechnology (Lake Placid, NY, USA); peroxidase-conjugated
goat anti-human Fc from Jackson ImmunoResearch Labora-
tories (West Grove, PA, USA). Secondary antibodies for
western blotting were as follows: rabbit-anti-goat Ig-horseradish
peroxidase (Zymed Laboratories Inc., San Francisco, CA,
USA); sheep-anti-mouse Ig-horseradish peroxidase (Amersham
Biosciences UK, Chalfont St Giles, UK).
Figure 8. Cartoon drawing of the DDR2 discoidin domain (selected side
chains: W52, cyan; R105, blue; E113, red) bound to a collagen peptide
(selected side chains: M21 and O24 of leading chain, F23 of middle chain).
Hydrogen bonds involving E113 are shown as dashed black lines. The
Figure was prepared using the coordinates of PDB entry 2WUH (6).
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Isolation of genomic DNA
Genomic DNA was isolated from the peripheral blood leuko-
cytes using Flexigene DNA Kit (Qiagen, GmbH) according to
the manufacturer’s instructions. DNA was dissolved in TE
(Tris-EDTA) buffer and quantitated by spectrophotometry.
Polymerase chain reaction (PCR)
Exon-specific primers for DDR2 gene (Supplementary
Material, Table S1) were designed using Primer3 (http://
frodo.wi.mit.edu/cgi-bin/primer3/) and used to amplify the
coding exons 3–18 and their flanking regions. Amplification
was carried out using 1U of Taq polymerase (Qiagen,
GmbH), 0.2 mM of each of the dNTPs, 1× PCR reaction
buffer, 1.5 mM MgCl2, 5 pmol of each forward and reverse
primers and 50 ng of genomic DNA template in 25 ml reac-
tions. The PCR was performed by an initial 5 min denaturation
at 958C followed by 40 cycles of 958C for 30 s, 588C–628C
for 35 s and 728C for 45 s with a final elongation at 728C
for 10 min.
DNA sequencing
Sequencing was performed using the dideoxy method by fluor-
escent automated sequencing on the ABI 3130xl genetic ana-
lyzer (Applied Biosystems, Foster City, CA, USA). The
sequence data were analysed using Sequencing analysis soft-
ware v5.3 (ABI, Foster City, CA, USA). Mutations are desig-
nated on the coding DDR2 sequence with reference to
GenBank accession number NM_001014796.1 with the A of
the initiation codon ATG as number +1.
Protein expression vectors
Construction of the HA-tagged DDR2 construct. The
HA-tagged version of the wild-type DDR2 was generated by
sequential site-directed mutagenesis to introduce the nine
amino acids of the HA tag (YPYDVPDYA) in two cycles
using the pcDNA3.1-DDR2 plasmid (21) as a template.
In the first cycle, we introduced five amino acids (YPYDV)
of the HA tag prior to the stop codon of the DDR2 gene
using the following mutagenesis primers.
HA1-F: CCACAAGGCGACGAGTACCCATACGATGTT
TGATGCTGTCAGTGCC and HA1-R: GGCACTGACAGCA
TCAAACATCGTATGGGTACTCGTCGCCTTGTGG. In
the second cycle, the above construct was used as a template
and the remaining four amino acids (PDYA) of the HA tag
were introduced using the following mutagenesis primers.
HA2-F: TACCCATACGATGTTCCAGATTACGCTTGATG
CTGTCAGTGCC and HA2-R: GGCACTGACAGCATCA
AGCGTAATCTGGAACATCGTATGGGTA.
Generation of missense DDR2 mutants. The missense mutants
were introduced by QuickChange site-directed mutagenesis
using Turbo Pfu polymerase (Stratagene) and using the
untagged pcDNA3.1-DDR2 (21) and the C-terminally
HA-tagged pcDNA3.1DDR2 as templates. The primers for
the site-directed mutagenesis to introduce the missense
mutations were as follows. DDR2-E113K-F: GAGGTCATGG
CATCAAGTTTGCCCCCATG; DDR2-E113K-R: CATGGG
GGCAAACTTGATGCCATGACCTC; DDR2-T713I-F: CG
AGATCTGGCCATTCGAAACTGTTTAG; DDR2-T713I-R:
CTAAACAGTTTCGAATGGCCAGATCTCG; DDR2-I726-F:
TACACAATCAAGAGAGCTGACTTTGGA; DDR2-I726R-
R: TCCAAAGTCAGCTCTCTTGATTGTGTA; DDR2-R752
C-F: GTGCTCCCTATCTGCTGGATGTCTTGG; DDR2-R75
2C-R: CCAAGACATCCAGCAGATAGGGAGCAC.
Generation of E113K ectodomain construct tagged with
human Fc. cDNA encoding E113K-DDR2 ectodomain
(Lys22-Thr398) was obtained by PCR amplification and
cloned into a modified pCEP-Pu vector containing a human
Fc sequence, as described for the respective wild-type and
W52A-DDR2 constructs (6).
All constructs were confirmed by direct DNA sequencing of
the purified plasmids.
Cell culture and transfection
HeLa cells were cultured in Dulbecco’s modified Eagle’s
medium (Invitrogen) supplemented with 10% fetal calf
serum, 2 mM L-glutamine and 100 U/ml penicillin/streptomy-
cin at 378C with 10% CO2. For transfection, cells were
grown in 24 well tissue culture plates. Transfection was per-
formed using the liposomal transfection reagent FuGENE 6
(Roche Biochemicals), according to manufacturer’s instruc-
tions. A mixture of 1 mg of DDR2 wild-type or mutant
plasmid DNA and 4 ml of FuGENE 6 in 94 ml of
OPTIMEM I medium was applied to each well of the cultured
cells. Twenty-four hours after transfection, the cells were fixed
and processed for microscopy.
Human embryonic kidney (HEK) 293 cells (ATCC, Mana-
ssas, VA, USA) and HEK293-EBNA cells (Invitrogen Ltd.,
Paisley, UK) were cultured in Dulbecco’s modified Eagle’s
medium/F12 medium (Invitrogen) supplemented with 10%
fetal bovine serum, penicillin (10 U/ml) and streptomycin
(100 mg/ml) at 378C with 5% CO2. For transfection, cells
were grown in 24 well tissue culture plates (autophosphoryla-
tion assays) or 12 well tissue culture plates (deglycosylation
assays) and were transfected with 1 or 2 mg, respectively, of
DDR2 wild-type or mutant plasmid DNA using calcium phos-
phate precipitation.
Immunohistochemistry
For immunofluorescence, cover slip-grown HeLa cells were
washed with phosphate-buffered saline (PBS), fixed by metha-
nol at 2208C for 4 min. Fixed cells were washed in PBS three
times then incubated in blocking solution (1% BSA in PBS)
for 30 min at room temperature. The fixed cells were then
incubated at room temperature for 1 h with either mouse
monoclonal anti-HA antibody alone or co-stained with both
mouse monoclonal anti-HA antibody and rabbit polyclonal
anti-calnexin antibody. After washing with PBS, the cells
were incubated with the appropriate secondary antibodies for
1 h at room temperature, washed several times with PBS and
mounted in immuno fluor medium (ICN Biomedicals). Data
were acquired using Leica DM-IRBE or Nikon confocal
microscopes. For presentation, images were pseudocolored
2248 Human Molecular Genetics, 2010, Vol. 19, No. 11
as either red (DDR2) or green (calnexin and EGFP-H-Ras),
contrast enhanced and overlayed using Adobe Photoshopw
(Adobe Inc.). All images presented are single sections in the
z-plane.
Deglycosylation assay
Forty hours after transfection, HEK293 cells were lysed in 1%
Nonidet P-40, 150 mM NaCl, 50 mM Tris, pH 7.4, 1 mM EDTA,
1 mM phenylmethylsulfonyl fluoride, 50 mg/ml aprotinin.
Twenty microliter of each cell lysate was denatured in 1X
glycoprotein denaturing buffer (0.5% SDS and 1%
b-mercaptoethanol) for 5 min at 1008C. The denatured lysates
were then split into two equal aliquots which were incubated
for 3 h at 378C in the presence or absence of 10 U of Endogly-
cosidase H. Samples were then resolved on 7.5% SDS–PAGE
followed by blotting onto nitrocellulose membranes and
probing with anti-DDR2 antibodies, as described below.
Collagen-induced DDR2 autophosphorylation
The assay was performed as described previously in detail
(21). Twenty-four hours after transfection, HEK293 cells
were incubated with serum-free medium for 16 h. Cells were
then stimulated with collagen I (2–50 mg/ml) for 90 min at
378C. Cells were lysed in 1% Nonidet P-40, 150 mM NaCl,
50 mM Tris, pH 7.4, 1 mM EDTA, 1 mM phenylmethylsulfonyl
fluoride, 50 mg/ml aprotinin, 1 mM sodium orthovanadate and
5 mM NaF. Aliquots of the lysates were analyzed by SDS–
PAGE followed by blotting onto nitrocellulose membranes.
The duplicate blots were probed with either anti-
phosphotyrosine monoclonal antibody or anti-DDR2 antibodies
followed by corresponding horseradish peroxidise-conjugated
secondary antibodies. Detection was performed using Enhanced
Chemiluminescence Plus (Amersham Biosciences) and an
Ettan DIGE Imager (GE Healthcare Biosciences).
Production and purification of recombinant proteins
The production and purification of recombinant DDR2 proteins
was essentially as previously described (6,21). The recombinant
Fc-tagged wild-type and E113K-DDR2 extracellular domain
proteins were isolated from episomally transfected HEK293-
EBNA cells and purified by affinity chromatography on a
HiTrap rProtein A column (17-5079-01, GE Healthcare Bio-
sciences, Uppsala, SW, USA) using an A¨KTATM Purifier (GE
Healthcare Biosciences). Both proteins were obtained in
similar yields (4.0 mg per liter of conditioned medium for wild-
type DDR2, 3.5 mg per liter of conditioned medium for
E113K-DDR2).
Solid-phase collagen binding assays
The assay procedure has been described previously in detail
(21). Briefly, rat tail collagen I or bovine collagen II was
diluted in 50 mM Tris pH 7.5, 100 mM NaCl to 10 mg/ml and
coated onto Maxisorp 96-well plates (Fisher Scientific) over-
night at room temperature. Wells were then blocked for 1 h
at room temperature with 1 mg/ml bovine serum albumin
in phosphate-buffered saline plus 0.05% Tween-20.
Recombinant Fc-tagged wild-type or mutant DDR2 extracellu-
lar domain proteins, diluted in incubation buffer (0.5 mg/ml
bovine serum albumin in phosphate-buffered saline plus
0.05% Tween 20), were added for 3 h at room temperature.
Wells were then washed six times with incubation buffer.
Bound Fc-tagged DDR2 proteins were then detected with
goat anti-human Fc coupled to horseradish peroxidase
(1:3333 dilution), added for 1 h at room temperature followed
by six washes with incubation buffer. A color reaction was
subsequently performed using o-phenylenediamine dihy-
drochloride (Sigma), added for 3–5 min. The reaction was
stopped with 3 M H2SO4, and plates were read at 492 nm on
a 96-well plate reader.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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